Abstract 337P
Background
To determine the percentage of breast cancers detectable by fused diffusion-weighted imaging (DWI) using unenhanced magnetic resonance imaging (MRI) and abbreviated post-contrast-enhanced MRI.
Methods
Between October 2016 and October 2017, 194 consecutive women (mean age, 54.2 years; age range, 28-82 years) with newly diagnosed unilateral breast cancer who underwent preoperative 3.0 T breast MRI with DWI were evaluated. Both fused DWI and abbreviated MRI images were independently reviewed by two radiologists for the detection of index cancer (which showed the most suspicious findings in both breasts), location, lesion conspicuity, lesion type, and lesion size. Moreover, the relationship between cancer detection and histopathological results of surgical specimens were evaluated.
Results
Index cancer detection rates were comparable between fused DWI and abbreviated MRI (radiologist 1: 174/194 [89.7%] vs. 184/194 [94.8%], respectively, P = 0.057; radiologist 2: 174/194 [89.7%] vs. 183/194 [94.3%], respectively, P = 0.092). In both radiologists, abbreviated MRI showed a significantly higher lesion conspicuity than fused DWI (radiologist 1: 9.37 ± 2.24 vs. 8.78 ± 3.03, P < 0.001; radiologist 2: 9.16 ± 2.32 vs. 8.39 ± 2.93, P < 0.001). The κ value for the interobserver agreement of index cancer detection was 0.67 on fused DWI and 0.85 on abbreviated MRI. For lesion conspicuity, the intraclass correlation coefficients were 0.72 and 0.82 on fused DWI and abbreviated MRI, respectively. Among the histopathological factors, tumor invasiveness was associated with cancer detection on both fused DWI (P = 0.011) and abbreviated MRI (P = 0.004, radiologist 1), lymphovascular invasion was associated with cancer detection on abbreviated MRI (P = 0.032, radiologist 1), and necrosis was associated with cancer detection on fused DWI (P = 0.031, radiologist 2).
Conclusions
Index cancer detection was comparable between fused DWI and abbreviated MRI, although abbreviated MRI showed a significantly better lesion conspicuity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
233P - Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital
Presenter: Marianela Bringas Beranek
Session: Poster session 02
235TiP - Hamlet.rt Trans: Prospective single-centre translational study evaluating liquid biomarkers of radiation response
Presenter: Mary Denholm
Session: Poster session 02
236TiP - Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD
Presenter: Shingo Kitagawa
Session: Poster session 02
247P - KN026 in combination with docetaxel as neoadjuvant treatment for HER2+ early or locally advanced breast cancer (BC): A single-arm, multicenter, phase II study
Presenter: Linxiaoxi Ma
Session: Poster session 02
248P - Targeting triple-negative breast cancer metabolism with neoadjuvant chemotherapy plus fasting-mimicking diet plus/minus metformin: The BREAKFAST trial
Presenter: Francesca Ligorio
Session: Poster session 02
250P - The impact of inter-cycle treatment delays on progression-free survival in early stage breast cancer
Presenter: Luke Steventon
Session: Poster session 02
251P - Body mass index as a predictive factor for efficacy of taxane-based chemotherapy in early breast cancer patients
Presenter: Jose Angel García-Sáenz
Session: Poster session 02